Short answer
Vanda Pharmaceuticals Inc. (VNDA) filed an 8-K current report with the SEC on February 23, 2026 reporting Item 8.01 (Other Events). FDA approved Bysanti (milsaperidone) for two indications: acute bipolar I manic/mixed episodes and schizophrenia in adults.
Vanda Pharmaceuticals Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA approved Bysanti (milsaperidone) for two indications: acute bipolar I manic/mixed episodes and schizophrenia in adults
- Dual-indication approval significantly expands addressable market: schizophrenia and bipolar disorder are large, chronic-treatment psychiatric conditions
- Bysanti approval represents a new commercial-stage asset for Vanda, potentially diversifying revenue beyond existing portfolio
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vanda Pharmaceuticals Inc. 8-K filings
Get the next VNDA 8-K as it lands
Follow VNDA for push alerts, or ask the research agent what this filing means.